Drug Database
Back to search

Poland· PL-100392095

Besponsa

A inotuzumab ozogamicin product containing inotuzumabum ozogamicini, registered in Poland by Pfizer Europe MA EEIG. The same ATC class is registered in 12 of our 19 countries.

ATC L01FB01

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedBesponsaATCL01FB01REGISTER NO.PL-100392095PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about inotuzumabum ozogamiciniAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Inotuzumab ozogamicin is registered in 12 of 19 countries.

Countries holding a registration under ATC L01FB01 (inotuzumab ozogamicin), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose
Search inotuzumab ozogamicin products by name

Inotuzumab ozogamicin · ATC L01FB01

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of inotuzumab ozogamicin costs, country by country.

Normalised to the WHO defined daily dose (0.1 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Inotuzumab ozogamicin · price per daily dose (0.1 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$1418.36
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
inotuzumabum ozogamicini
Manufacturer
Pfizer Europe MA EEIG
Country
Poland (PL)
ATC code
L01FB01
ATC class
Inotuzumab ozogamicin
Defined daily dose
0.1 mg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05907636977193

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

362 interactions on record for inotuzumab ozogamicin.

Graded by severity as the source publishes them — 96 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check inotuzumab ozogamicin against other medicinesHow interaction checks work

Inotuzumab ozogamicin · interactions on record

362 records

  • 96 severe
  • 263 moderate
  • 3 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • QuinidineC01BA01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Inotuzumab ozogamicin in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All inotuzumab ozogamicin products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Besponsa
  • Liechtenstein · Besponsa
  • Norway · Besponsa

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/7b6cf81e-69a0-4b2c-9d49-5f1f540db2f2
GET /v1/drugs/7b6cf81e-69a0-4b2c-9d49-5f1f540db2f2?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Proszek do sporządzania koncentratu roztworu do infuzji",
  "source": "urpl",
  "strength": "1 mg",
  "packaging": "05907636977193 ¦ Rpz ¦ EU/1/17/1200/001 ¦ 123854\n1 fiol. 1 mg proszku",
  "substance": "inotuzumabum ozogamicini 1 mg",
  "common_name": "inotuzumabum ozogamicini",
  "pl_product_id": "100392095",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about inotuzumab ozogamicin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console